Influence of chronic HBV infection on superimposed acute hepatitis E

World Journal of Gastroenterology

Volumn 19, Issue 35, 2013, Pages 5904-5909

  Cheng, Si Hong ^a   Mai, Li ^a   Zhu, Feng Qin ^a   Pan, Xing Fei ^a   Sun, Hai Xia ^a   Cao, Hong ^a   Shu, Xin ^a   Ke, Wei Min ^a   Li, Gang ^a   Xu, Qi Huan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Acute hepatitis E; Anti hepatitis B virus treatment; Chronic hepatitis B virus infection; Clinical profile; Superinfection

Indexed keywords

BILIRUBIN; ENTECAVIR; HEPATITIS B (E) ANTIGEN; LAMIVUDINE; UNCLASSIFIED DRUG; VIRUS DNA;

ACUTE HEPATITIS; ADULT; ARTICLE; CHRONIC HEPATITIS; COMPARATIVE STUDY; FEMALE; HEPATITIS B; HEPATITIS E; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; MORBIDITY; MORTALITY; PROTHROMBIN TIME; RETROSPECTIVE STUDY; SUPERINFECTION;

ACUTE HEPATITIS E; ANTI-HEPATITIS B VIRUS TREATMENT; CHRONIC HEPATITIS B VIRUS INFECTION; CLINICAL PROFILE; SUPERINFECTION;

ACUTE DISEASE; ADULT; AGED; ANTIVIRAL AGENTS; BILIRUBIN; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CHINA; COINFECTION; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS E; HUMANS; LIVER CIRRHOSIS; LIVER FAILURE; MALE; MIDDLE AGED; PREVALENCE; PROTHROMBIN TIME; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84885590811     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i35.5904     Document Type: Article

References (29)

1. Fact sheet No 204 of World Health Organization. Available from: URL: http://www.who.int/mediacentre/factsheets/ fs204/en/
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107 [PMID: 14996343 DOI: 10.1046/j.1365-2893.2003.00487.x]
3. Xiong LS, Cui SF, Zhou JG, Xing Y. [Detection and analysis of HAV-HEV, HGV infection in patients with viral hepatitis]. Zhonghua Ganzangbing Zazhi 2004; 12: 395-396 [PMID: 15268800]
4. Kumar M, Sharma BC, Sarin SK. Hepatitis E virus as an etiology of acute exacerbation of previously unrecognized asymptomatic patients with hepatitis B virus-related chronic liver disease. J Gastroenterol Hepatol 2008; 23: 883-887 [PMID: 18070014 DOI: 10.1111/j.1440-1746.2007.05243.x]
5. Ke WM, Li XJ, Yu LN, Lai J, Li XH, Gao ZL, Chen PJ. Etiological investigation of fatal liver failure during the course of chronic hepatitis B in southeast China. J Gastroenterol 2006; 41: 347-351 [PMID: 16741614 DOI: 10.1007/s00535-005-1781-y]
6. Zhang GS, Feng FM, Li YL, Yuan JX, Shang H. A study of chronic hepatitis B infection superinfected with hepatitis E infection. Zhonghua Ganzangbing Zazhi 2006; 14: 906-908 [PMID: 17196134]
7. Ramachandran J, Eapen CE, Kang G, Abraham P, Hubert DD, Kurian G, Hephzibah J, Mukhopadhya A, Chandy GM. Hepatitis E superinfection produces severe decompensation in patients with chronic liver disease. J Gastroenterol Hepatol 2004; 19: 134-138 [PMID: 14731121 DOI: 10.1111/ j.1440-1746.2004.03188.x]
8. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242 [PMID: 19054588 DOI: 10.1016/j.jhep.2008.10.001]
9. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-283 [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3]
10. Miyake Y, Iwasaki Y, Takaki A, Fujioka S, Takaguchi K, Ikeda H, Kobashi H, Sakaguchi K, Shiratori Y. Lamivudine treatment improves the prognosis of fulminant hepatitis B. Intern Med 2008; 47: 1293-1299 [PMID: 18628576 DOI: 10.2169/internalmedicine.47.1061]
11. Jochum C, Gieseler RK, Gawlista I, Fiedler A, Manka P, Saner FH, Roggendorf M, Gerken G, Canbay A. Hepatitis B-associated acute liver failure: immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae. Digestion 2009; 80: 235-240 [PMID: 19828954 DOI: 10.1159/000236009]
12. Huang K, Hu JH, Wang HF, He WP, Chen J, Duan XZ, Zhang AM, Liu XY. Survival and prognostic factors in hepatitis B virus-related acute-on-chronic liver failure. World J Gastroenterol 2011; 17: 3448-3452 [PMID: 21876637 DOI: 10.3748/wjg.v17.i29.3448]
13. Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 2011; 53: 774-780 [PMID: 21294143 DOI: 10.1002/hep.24109]
14. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-871 [PMID: 10733541]
15. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, Wolfe RA, Krom R. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-96 [PMID: 12512033 DOI: 10.1053/gast.2003.50016]
16. Chan HL, Chim AM, Lau JT, Hui AY, Wong VW, Sung JJ. Evaluation of model for end-stage liver disease for predic-tion of mortality in decompensated chronic hepatitis B. Am J Gastroenterol 2006; 101: 1516-1523 [PMID: 16863555 DOI: 10.1111/j.1572-0241.2006.00659.x]
17. Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Diagnostic and treatment guidelines for liver failure. Zhonghua Ganzangbing Zazhi 2006; 14: 643-646 [PMID: 16995974]
18. Coursaget P, Buisson Y, N'Gawara MN, Van Cuyck-Gandre H, Roue R. Role of hepatitis E virus in sporadic cases of acute and fulminant hepatitis in an endemic area (Chad). Am J Trop Med Hyg 1998; 58: 330-334 [PMID: 9546413]
19. Dudley FJ, Fox RA, Sherlock S. Cellular immunity and hepatitis-associated, Australia antigen liver disease. Lancet 1972; 1: 723-726 [PMID: 4111197 DOI: 10.1016/ S0140-6736(72)90234-6]
20. Huang CF, Lin SS, Ho YC, Chen FL, Yang CC. The immune response induced by hepatitis B virus principal antigens. Cell Mol Immunol 2006; 3: 97-106 [PMID: 16696896]
21. Rehermann B. Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses. Semin Liver Dis 2007; 27: 152-160 [PMID: 17520515 DOI: 10.1055/s-2007-979468]
22. Shimizu Y. T cell immunopathogenesis and immunotherapeutic strategies for chronic hepatitis B virus infection. World J Gastroenterol 2012; 18: 2443-2451 [PMID: 22654441 DOI: 10.3748/wjg.v18.i20.2443]
23. Chu CM, Liaw YF. Peripheral T-cell subsets in asymptomatic hepatitis B-virus carriers. Cell Immunol 1986; 98: 533-537 [PMID: 3489555 DOI: 10.1016/0008-8749(86)90312-6]
24. Tian Y, Qiu ZF, Li TS. Difference and significance of peripheral blood T-lymphocyte subsets in patients with chronic hepatitis B and asymptomatic HBV carriers. Zhonghua Yixue Zazhi 2005; 85: 3354-3358 [PMID: 16409844]
25. Ikeda T, Lever AM, Thomas HC. Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life. Hepatology 1986; 6: 962-965 [PMID: 2428724 DOI: 10.1002/hep.1840060525]
26. Akpolat N, Yahsi S, Godekmerdan A, Demirbag K, Yalniz M. Relationship between serum cytokine levels and histopathological changes of liver in patients with hepatitis B. World J Gastroenterol 2005; 11: 3260-3263 [PMID: 15929178]
27. Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy PT, Lampertico P, Das A, Lopes AR, Borrow P, Williams K, Humphreys E, Afford S, Adams DH, Bertoletti A, Maini MK. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 2007; 204: 667-680 [PMID: 17353365 DOI: 10.1084/jem.20061287]
28. Akcam FZ, Tigli A, Kaya O, Ciris M, Vural H. Cytokine levels and histopathology in chronic hepatitis B and chronic hepatitis C. J Interferon Cytokine Res 2012; 32: 570-574 [PMID: 23067363 DOI: 10.1089/jir.2012.0048]
29. Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, Wang H, Yang CL, Jiang HM, Cai JP, Wang YJ, Ai X, Hu YM, Tang Q, Yao X, Yan Q, Xian YL, Wu T, Li YM, Miao J, Ng MH, Shih JW, Xia NS. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010; 376: 895-902 [PMID: 20728932 DOI: 10.1016/ S0140-6736(10)61030-6]